

Diabetic gastroparesis - Pipeline Insight, 2021

<https://marketpublishers.com/r/D0F417A823FEN.html>

Date: May 2021

Pages: 70

Price: US\$ 1,500.00 (Single User License)

ID: D0F417A823FEN

Abstracts

This report can be delivered to the clients within 48 hours

DelveInsight's, "Diabetic gastroparesis - Pipeline Insight, 2021," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Diabetic gastroparesis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Diabetic gastroparesis Understanding

Diabetic gastroparesis: Overview

Diabetic gastroparesis refers to cases of the digestive condition gastroparesis that is caused by diabetes. The symptoms of gastroparesis vary in severity from person to person and may include any combination of the nausea and vomiting, heartburn, loss of appetite, weight loss, bloating, unstable blood sugar levels, gastroesophageal reflux and/or stomach spasms. Gastroparesis is more common in females than males, and in people who have had surgery around the esophagus, stomach, or small intestine, as surgery can affect the vagus nerve. The American College of Gastroenterology (ACG) guidelines for the diagnosis and management of Diabetic gastroparesis state that a combination of appropriate symptoms and signs, along with delayed gastric emptying in the absence of gastric outlet obstruction or ulceration, is required to establish the

diagnosis of Diabetic gastroparesis. The treatments for Diabetic gastroparesis include nutritional assessment and dietary modifications, glycemic control, prokinetic agents and antiemetic agents.

'Diabetic gastroparesis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Diabetic gastroparesis pipeline landscape is provided which includes the disease overview and Diabetic gastroparesis treatment guidelines. The assessment part of the report embraces, in depth Diabetic gastroparesis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diabetic gastroparesis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Diabetic gastroparesis R&D. The therapies under development are focused on novel approaches to treat/improve Diabetic gastroparesis.

Diabetic gastroparesis Emerging Drugs Chapters

This segment of the Diabetic gastroparesis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Diabetic gastroparesis Emerging Drugs

Nimacimab: Bird Rock Bio

Nimacimab is a first-in-class peripheral antagonist antibody to cannabinoid receptor 1 (CB1) for the treatment of fibrotic, metabolic, and inflammatory diseases including nonalcoholic steatohepatitis (NASH) and diabetic kidney disease (DKD). The drug is in

Phase II clinical studies for the treatment of Diabetic gastroparesis.

NG101: Neurogastrx

NG101 is a potent, selective and peripherally restricted dopamine D2 receptor antagonist. The drug is in Phase II clinical evaluation for the treatment of Diabetic gastroparesis. Neurogastrx has generated preclinical data indicating that in addition to its potent antiemetic properties, NG101 is also expected to significantly increase gastric motility, conferring NG101 an ideal pharmacological profile for the treatment of gastroparesis.

Further product details are provided in the report

Diabetic gastroparesis: Therapeutic Assessment

This segment of the report provides insights about the different Diabetic gastroparesis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Diabetic gastroparesis

There are approx. 10+ key companies which are developing the therapies for Diabetic gastroparesis. The companies which have their Diabetic gastroparesis drug candidates in the most advanced stage, i.e. Phase III include, Vanda Pharmaceuticals.

Phases

DelveInsight's report covers around 8+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Diabetic gastroparesis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravitreal

Subretinal

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Diabetic gastroparesis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Diabetic gastroparesis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diabetic gastroparesis drugs.

Diabetic gastroparesis Report Insights

- Diabetic gastroparesis Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Diabetic gastroparesis Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Diabetic gastroparesis drugs?

How many Diabetic gastroparesis drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Diabetic gastroparesis?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Diabetic gastroparesis therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Diabetic gastroparesis and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Bird Rock Bio

Neurogastrx

Vanda Pharmaceuticals

Takeda

GlaxoSmithKline

Theravance Biopharma

PTC Therapeutics

Key Products

Nimacimab

NG101

Tradipitant

TAK-906 Maleate

Camicinal

TD-1473

Sepiapterin

Contents

Introduction

Executive Summary

Diabetic gastroparesis: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Diabetic gastroparesis – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Diabetic gastroparesis companies' collaborations, Licensing, Acquisition -Deal Value

Trends

Diabetic gastroparesis Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Tradipitant: Vanda Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Mid Stage Products (Phase II)

Comparative Analysis

Nimacimab: Bird Rock Bio

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Early Stage Products (Phase I)

Comparative Analysis

Drug name: Company name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Preclinical and Discovery Stage Products

Comparative Analysis

Drug name: Company name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Inactive Products

Comparative Analysis

Diabetic gastroparesis Key Companies

Diabetic gastroparesis Key Products

Diabetic gastroparesis- Unmet Needs

Diabetic gastroparesis- Market Drivers and Barriers

Diabetic gastroparesis- Future Perspectives and Conclusion

Diabetic gastroparesis Analyst Views

Diabetic gastroparesis Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Diabetic gastroparesis

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Diabetic gastroparesis

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Diabetic gastroparesis - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/D0F417A823FEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/D0F417A823FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970